The Influence of Acenocumarole on the Fibrinogen-turnover in Normal Subjects, Venous Thrombosis and Congestive Heart Failure

A. P. C. van der Maas; F. A. G Teulings; W Schopman; G. J. H. den Ottolander

doi:10.1055/s-0038-1649034

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1972; 28(03): 496-508
DOI: 10.1055/s-0038-1649034

Original Article

Schattauer GmbH

The Influence of Acenocumarole on the Fibrinogen-turnover in Normal Subjects, Venous Thrombosis and Congestive Heart Failure

A. P. C. van der Maas

¹Department of Internal Medicine D and Laboratory for Endocrinological Chemistry, Municipal Hospital Bergweg, Rotterdam, Department of Biochemical Research, Rotterdamsch Radio-Therapeutisch Instituut, Rotterdam (the Netherlands)

,

F. A. G Teulings

¹Department of Internal Medicine D and Laboratory for Endocrinological Chemistry, Municipal Hospital Bergweg, Rotterdam, Department of Biochemical Research, Rotterdamsch Radio-Therapeutisch Instituut, Rotterdam (the Netherlands)

,

W Schopman

¹Department of Internal Medicine D and Laboratory for Endocrinological Chemistry, Municipal Hospital Bergweg, Rotterdam, Department of Biochemical Research, Rotterdamsch Radio-Therapeutisch Instituut, Rotterdam (the Netherlands)

,

G. J. H. den Ottolander

¹Department of Internal Medicine D and Laboratory for Endocrinological Chemistry, Municipal Hospital Bergweg, Rotterdam, Department of Biochemical Research, Rotterdamsch Radio-Therapeutisch Instituut, Rotterdam (the Netherlands)

› Author Affiliations

Abstract

Summary

Using ¹³¹Iodine-tagged fibrinogen the influence of acenocumarole on the biological half-life of fibrinogen was investigated in healthy patients, patients with venous thrombosis and patients with congestive heart failure.

In 16 healthy patients the mean t½ was 3.8 days. In two of them after administration of acenocumarole the t½ was lengthened. This supports the opinion of a continuous deposition of fibrin on the vascular endothelium in the hemostatic balance.

In 13 patients with venous thrombosis the mean t½ was 2.45 days, lengthening to the normal range after acenocumarole therapy. The time interval between the start of acenocumarole therapy and the moment of normalization of the t½ was approximately 4 days. The prothrombin time-index at this moment was 2.3 (thrombotest 5%), which argues in favour of a vigorous anticoagulant therapy.

In our 10 patients with congestive heart failure probably venous thrombosis occurred in 40%. Prophylactic anticoagulant therapy as in surgical patients therefore has to be considered.

Full Text

References

References
1 Adelson E, Rheingold J. J, Parker O, Buenaventura A, and Crosby W. H. 1961; Platelet and fibrinogen survival in normal and abnormal states of coagulation. Blood 17: 267.
2 Alkjaersig N, Fletcher A. P, and Sherry S. 1959; The mechanism of clotdissolution by plasmin. Journal of Clinical Investigation 38: 1086.
3 Amris A, and Amris C. J. 1964; Turnover and distribution of ¹³¹iodine-labelled human fibrinogen. Thrombosis et Diathesis Haemorrhagica 11: 404.
4 Astrup T, and Mullertz S. 1952; The fibrin plate method for estimating fibrinolytic activity. Archives of Biochemistry and Biophysics 40: 346.
5 Atencio A. C, Baily H. R, and Reeve E. B. 1965; Studies on the metabolism and distribution of fibrinogen in young and older rabbits. I. Methods and models. Journal of Laboratory and Clinical Medicine 69: 624.
6 Christensen L. K. 1958; The turnover of plasma fibrinogen. Acta Medica Scandinavica 162: 407.
7 Clement W. E, and MuNicol G. P. 1959; The preparation and use of ¹³¹I-tagged fibrinogen to demonstrate fibrinolysis. Journal of Clinical Pathology 12: 544.
8 Collen D, Tytgat G. N, Claeys H, and Piessens R. 1972; I. Fibrinogen turnover in physiological conditions in humans. British Journal of Haematology 22: 681.
9 Feaenlby G. R, and Tweed J. M. 1953; An active fibrinolytic enzyme in plasma of normal people with observations on inhibition associated with the presence of calcium. Clinical Science 12: 81.
10 Fearnley G. R, and Lacknee R. 1955; The fibrinolytic activity of normal blood. British Journal of Haematology 1: 189.
11 Fearnley G. R. 1960; Spontaneous fibrinolysis. American Journal of Cardiology 6: 371.
12 Gajewski J, and Alexander B. 1963; Effect of epsilon aminocaproic acid on the turnover of labelled fibrinogen in rabbits. Circulation Research 13: 432.
13 Hammond J. D. S, and Veeel D. 1959; Observations on the distribution and biological half-life of human fibrinogen. British Journal of Haematology 5: 431.
14 Hart H. C. 1966. The biological half-life of ¹³¹I-fibrinogen. Academical thesis; Utrecht, the Netherlands:
15 Hickman J. A. 1970; The pharmacological enhancement of fibrinolytic activity and ¹²⁵I-fibrino-gen survival. Journal of Clinical Pathology 23: 797.
16 Hickman J. A. 1971; A new Technique for the Quantitative Estimation of Fibrinolysis using in vivo ¹²⁵I-fibrinogen. British Journal of Haematology 20: 611.
17 Jeyasingh K, Maurer B, Rosengarten D. S, and Verma T. R. 1970; Decline of blood activity of ¹²⁵I-fibrinogen in venous thrombosis. Lancet 12: 294.
18 Lewis J. H, Ferguson E. E, and Schoenfeld C. 1961; Studies concerning the turnover of fibrinogen-I¹³¹ in the dog. Journal of Laboratory and Clinical Medicine 75: 355.
19 Maas A. P. C. van der, Teulings F. A. G, and Ottolanderden G. J. H. 1971; The use of labelled fibrinogen in the diagnosis of venous thrombosis. Thrombosis et Diathesis Haemorrhagica 26: 1.
20 Madden R. E, and Gould R. G. 1952; Turnover rate of plasma fibrinogen. Federation Proceedings 11: 252.
21 McFarlane A. S. 1958; Efficient tracer-labelling of proteins with iodine. Nature (London) 182: 53.
22 McFarlane A. S. 1963; In vivo behaviour of ¹³¹I-fibrinogen. Journal of Clinical Investigation 42: 346.
23 Nilehn J. E, and Nilsson I. M. 1964; Demonstration of fibrinolytic split products in human serum by an immunological method in spontaneous and induced fibrinolytic states. Scandinavion Journal of Haematology 1: 313.
24 Rausen A. R, Cruchaud A, McMillan C. W, and Gitlin D. 1961; A study of fibrinogen turnover in classical hemophilia and congenital afibrinogenemia. Blood 18: 710.
25 Regoeczi E. 1966. Labelled Proteins in Tracer Studies. Euratom; Brussels: 85.
26 Regoeczi E. 1967; Measuring the coagulability of fibrinogen in plasma by isotopie means: Method and principles of the use for in vivo studies. Thrombosis et Diathesis Haemorrhagica 18: 276.
27 Regoeczi E. 1971; Iodine-labelled fibrinogen: A review. British Journal of Haematology 20: 649.
28 Rosa U, Scasselati G. A, Pennisi F, Riccione N, Giagnoni P, and Giordiani R. 1964; Biochimical and Biophysical Acta 86: 519.
29 Sawyer W. D, Fletcher A. P, Alkjaersig N, and Sherry S. 1960; Studies on the thrombolytic activity of human plasma. Journal of Clinical Investigation 39: 426.
30 Takeda Y. 1966; Studies of the metabolism and distribution of fibrinogen in healthy men with autologous ¹²⁵I-labelled fibrinogen. Journal of Clinical Investigation 45: 103.
31 Takeda Y. 1967; Studies of the metabolism and distribution of fibrinogen in patients with rheumatoid arthritis. Journal of Laboratory and Clinical Medicine 69: 624.
32 Takeda Y. 1970; Studies of the effects of heparin, Coumadin, and vitamin K on prothrombin metabolism and distribution in calves with the use of iodine-125-prothrombin. Journal of Laboratory and clinical Medicine 75: 355.
33 Teulings F. A. G, and Biggs G. J. 1970; Study of electrolytic labelling of fibrinogen with ¹³¹-Iodine by Sephadex G-10 gel filtration. Clinical chimica Acta 27: 57.
34 Tytgat G. N, Collen D, and Verstraete M. 1971; Metabolism of Fibrinogen in Cirrhosis of the liver. Journal of Clinical Investigation 50: 1690.
35 Tytgat G. N, Collen D, and Vermylen J. 1972; II. Fibrinogen turnover in polycytaemia, thrombocytosis, haemophilia A, congenital afibrinogenaemia and during streptokinase therapy. British Journal of Haematology 22: 701.
36 Volwiler W, Goldswoethy P. D, MacMartin M. P, Wood P. A, MacKay I. R, and Fremont-Smith K. 1955; Biosynthetic determination with radioactive sulfur of turn-over rates of various plasma proteins in normal and cirrhotic man. Journal of Clinical Investigation 34: 1126.